Aclaris Therapeutics (ACRS)
(Delayed Data from NSDQ)
$1.23 USD
0.00 (0.00%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $1.25 +0.02 (1.63%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Aclaris Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 119 | 218 | 191 | 54 | 75 |
Receivables | 0 | 0 | 1 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 9 | 14 | 13 | 3 | 8 |
Total Current Assets | 129 | 232 | 205 | 57 | 84 |
Net Property & Equipment | 2 | 1 | 1 | 2 | 2 |
Investments & Advances | 63 | 12 | 34 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 7 | 7 | 7 | 7 |
Deposits & Other Assets | 4 | 3 | 4 | 5 | 5 |
Total Assets | 197 | 255 | 251 | 71 | 98 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 9 | 10 | 10 | 5 | 10 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 19 | 9 | 10 | 6 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 2 | 2 | 3 | 4 |
Total Current Liabilities | 31 | 22 | 23 | 15 | 22 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 11 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 9 | 35 | 31 | 7 | 5 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 40 | 57 | 54 | 33 | 28 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 928 | 881 | 793 | 542 | 524 |
Retained Earnings | -771 | -682 | -595 | -505 | -454 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 157 | 198 | 197 | 38 | 70 |
Total Liabilities & Shareholder's Equity | 197 | 255 | 251 | 71 | 98 |
Total Common Equity | 157 | 198 | 197 | 38 | 70 |
Shares Outstanding | 70.80 | 66.60 | 61.20 | 42.90 | 41.30 |
Book Value Per Share | 2.22 | 2.97 | 3.22 | 0.88 | 1.69 |
Fiscal Year End for Aclaris Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 119 | 103 | 120 | 171 |
Receivables | NA | 0 | 0 | 0 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 9 | 20 | 13 | 13 |
Total Current Assets | NA | 129 | 123 | 133 | 184 |
Net Property & Equipment | NA | 2 | 2 | 2 | 2 |
Investments & Advances | NA | 63 | 84 | 91 | 34 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 7 | 7 | 7 |
Deposits & Other Assets | NA | 4 | 3 | 3 | 3 |
Total Assets | NA | 197 | 218 | 236 | 230 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 9 | 10 | 11 | 8 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 19 | 15 | 9 | 7 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 2 | 2 | 2 | 2 |
Total Current Liabilities | NA | 31 | 27 | 23 | 18 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 34 | 33 | 34 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 40 | 62 | 56 | 53 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 928 | 927 | 921 | 888 |
Retained Earnings | NA | -771 | -769 | -740 | -710 |
Other Equity | NA | 0 | -1 | -1 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 157 | 156 | 180 | 177 |
Total Liabilities & Shareholder's Equity | NA | 197 | 218 | 236 | 230 |
Total Common Equity | 0 | 157 | 156 | 180 | 177 |
Shares Outstanding | 70.90 | 70.80 | 70.80 | 70.60 | 70.60 |
Book Value Per Share | 0.00 | 2.22 | 2.21 | 2.55 | 2.50 |